This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lohmann, K. L. Articles by Moore, J. N. Search for Related Content PubMed PubMed Citation Articles by Lohmann, K. L. Articles by Moore, J. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Lipopolysaccharide from Rhodobacter sphaeroides is an agonist in equine cells

Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

Michel Vandenplas

Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

Michelle H. Barton

Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

James N. Moore

Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

Endotoxemia is associated with the principal causes of death in adult horses and equine neonates and, therefore, veterinary researchers are expending efforts to identify new therapeutic interventions that might be beneficial in these animals. Endotoxin antagonists inhibit interaction of endotoxin with cellular receptors and may be beneficial in the treatment of endotoxemia and sepsis. Diphosphoryl lipid A from Rhodobacter sphaeroides (RsDPLA) is a potent antagonist of enteric LPS in human cells, but is an agonist in hamster cells. In this study, the effect of lipopolysaccharide from R. sphaeroides (RsLPS) on equine whole blood and isolated monocyte preparations was investigated by comparing tumor necrosis factor (TNF) production in response to RsLPS and Escherichia coli O55:B5 LPS. Our results indicate that RsLPS is a potent agonist in equine cells, which precludes therapeutic use of this agent in equine patients. In contrast to the results in equine cells, RsLPS did not elicit TNF production by itself, and inhibited the response to E. coli O55:B5 LPS in a human monocytic cell line.

Journal of Endotoxin Research, Vol. 9, No. 1, 33-37 (2003)
DOI: 10.1177/09680519030090010301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?